<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl1">
 <label>Table 1</label>
 <caption>
  <p>Mechanisms of action and targets of potential treatment agents for SARS-CoV-2 infections.</p>
 </caption>
 <alt-text id="alttext0010">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Mechanism of action and targets</th>
    <th>Drugs</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Inhibition of the RNA-dependent RNA polymerase</td>
    <td>Remdesivir
     <break/>Favipiravir
     <break/>Ribavirin
    </td>
   </tr>
   <tr>
    <td>Inhibition of spike protein on SARS-CoV-2 (non-endosomal pathway)</td>
    <td>TMPRSS2 inhibitor (camostat mesylate)</td>
   </tr>
   <tr>
    <td>Inhibition of endosomal acidification (early endosomal pathway)</td>
    <td>Chloroquine, hydroxychloroquine (azithromycin is reported to greatly enhance the anti-SARS-CoV-2 activity of hydroxychloroquine)</td>
   </tr>
   <tr>
    <td>Inhibition of viral exocytosis</td>
    <td>Interferon-α 2a
     <break/>Interferon-β 1b
    </td>
   </tr>
   <tr>
    <td>Inhibition of papain-like protease and 3C-like protease</td>
    <td>Lopinavir/ritonavir</td>
   </tr>
   <tr>
    <td>Inhibition of cathepsin L and cathepsin B in host cells (late endosomal pathway)</td>
    <td>Teicoplanin (other glycopeptides including dalbavancin, oritavancin, and telavancin)</td>
   </tr>
   <tr>
    <td>Enhancement of the anti-SARS-CoV-2 activity of hydroxychloroquine</td>
    <td>Azithromycin</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
